CD8A and neoplasm: We hypothesized that talimogene laherparepvec, an oncolytic HSV expressing human granulocyte macrophage colony stimulating factor (GMCSF), will have an additive effect to the drug combination, trabectedin and nivolumab, by inducing local oncolysis which would expose tumor neoantigens in the TME, by evoking macrophage maturation to dendritic cells, differentiation of M2 growth promoting macrophages to M1 killer macrophages which will then recruit CD8 killer T cells into the TME for tumor antigen recognition and restoration of normal tumor surveillance function.